Loading stock data…
$12.63-0.18 (-1.44%)
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
Novavax, Inc. in the Healthcare sector is trading at $12.63 with a market capitalization of $1.5B. Wall Street consensus targets $14.11 (9 analysts), implying a +11.7% move over the next 12 months. The stock is currently near its 52-week high of $13.39, remaining 38.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $56.70M↓ | $139.51M↓ | $147.14M↑ | $70.44M↓ | $239.24M |
| Gross Profit | $42.45M↓ | $108.82M↓ | $125.03M↑ | $48.95M↓ | $223.91M |
| Operating Income | -$54.91M↓ | -$15.43M↓ | $15.04M↑ | -$80.98M↓ | $101.07M |
| Net Income | -$53.39M↓ | -$9.49M↓ | $17.53M↑ | -$202.38M↓ | $106.51M |
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-1...